Further studies will attempt to address two aspects: first, study the mechanism by which Betulin-treated cells or SREBP-1 knockdown cells become less resistant to Sorafenib; second, prove the accessibility that SREBP-1 becomes a prognosis marker of HCC patients. The gene discussed is SREBF1; the disease is hepatocellular carcinoma.